PSMA SR6

Drug Profile

PSMA SR6

Alternative Names: 177Lu-PSMA-SR6; 68Ga-PSMA-SR6

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Advanced Accelerator Applications; Johns Hopkins University
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
  • 11 Jan 2016 PSMA SR6 licensed to Advanced Accelerator Applications
  • 11 Jan 2016 Preclinical trials in Prostate cancer (Diagnosis) in USA and France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top